Photo Credit: freepik
The following is a summary of “Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis,” published in the September 2024 issue of Ophthalmology by Deng et al.
VEGF causes abnormal blood vessel growth in the eye, making anti-VEGF drugs crucial for eye treatments.
Researchers conducted a retrospective study evaluating how anti-VEGF agents have been used in ophthalmology over the last 20 years to guide future research.
They thoroughly searched the Web of Science Core Collection from 2003 to 2023. The gathered literature was analyzed using VOSviewer, CiteSpace, and the Bibliometrix R package.
The results showed that 3,602 publications were analyzed from 83 countries and 3,445 institutions. The U.S. and China made the most contributions. Johns Hopkins University, the University of Sydney, and Genentech Inc. led in output. “Retina” had the most publications, while “Ophthalmology” was cited the most. Bressler NM, Holz FG, Glassman AR, and Bandello F published the most, with Brown DM being the most cited author. Key terms were “Endothelial Growth Factor,” “therapy,” “Safety,” and “Randomized Clinical Trial.”
Investigators concluded that anti-VEGF drugs are effective for treating neovascular eye diseases. Future improvements include new drugs, better delivery systems, non-invasive methods, and AI, which could lead to safer and more cost-effective treatments.
Source: link.springer.com/article/10.1007/s10792-024-03299-z
